Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2026 07:00 ET | Source: GH Research PLC

GH Research Reports Full Year 2025 Financial Results and Provides Business Update

Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congressesGH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCash,...
January 05, 2026 07:00 ET | Source: GH Research PLC

GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026

GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating Phase 2b designPhase 3 initiation targeted for...
January 02, 2026 16:01 ET | Source: GH Research PLC

GH Research to Announce IND Status for GH001

DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing...
November 06, 2025 07:00 ET | Source: GH Research PLC

GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates

Engagement with FDA on GH001 IND complete response ongoingFull dataset from the Phase 2b clinical trial of GH001 in TRD reported in July 2025Long-term clinical data on safety and efficacy from...
October 09, 2025 07:00 ET | Source: GH Research PLC

GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress

DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing...
August 07, 2025 07:00 ET | Source: GH Research PLC

GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates

Global pivotal program initiation on track for 2026Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months...
July 23, 2025 08:00 ET | Source: GH Research PLC

GH Research Announces Global Pivotal Program Plans and Further Development Updates

Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no...
June 20, 2025 13:00 ET | Source: GH Research PLC

GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule

DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing...
May 15, 2025 07:00 ET | Source: GH Research PLC

GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting

DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing...
May 08, 2025 07:00 ET | Source: GH Research PLC

GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates

Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track for submission in mid-2025Cash, cash...